Drug intelligence / Profile preview

DPH60X

Development stage: Preclinical
Lead developer: Disruptive Pharma
Modality: Small Molecules
Administration: Oral

Overview

DPH60X is a preclinical-stage oral small molecule drug candidate being developed by Disruptive Pharma. It represents a reformulation of an established active pharmaceutical ingredient (API) utilizing the company's proprietary Formulite technology. This platform employs mesoporous magnesium carbonate (MMC) to enhance the solubility and oral bioavailability of drugs that are otherwise poorly soluble. While the specific API and molecular target have not been disclosed, the candidate is part of a pipeline with an initial focus on oncology and other therapeutic areas where improved drug delivery is required.

Beyond the preview

Go deeper on DPH60X.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DPH60X.

Explore the full profile